



**Media Advisory: 4<sup>th</sup> International Conference on Clinical Trials in Alzheimer's Disease, November 3-5, 2011 in San Diego, California.**

Alzheimer's Disease (AD) researchers from around the world will gather in San Diego, California, November 3-5 for the Fourth International Conference on Clinical Trials for Alzheimer's Disease (CTAD). The Conference will highlight the urgency of developing new treatments for AD, a progressive and ultimately fatal neurodegenerative disease that today affects more than 35 million individuals worldwide, robbing them of their memory, independence, and ability to think and understand. By 2050, the number of people with AD is expected to triple, placing an incomprehensible strain on governments and public health systems worldwide if nothing is done to slow or prevent the disease.

In recent years, scientists have made major advances in understanding how the disease ravages the brain. Yet despite these discoveries, no new drug has been approved since 2003 and the drugs that are currently available treat symptoms only, rather than modifying the disease process itself. Speakers at CTAD 2011 will address many of the reasons for this lack of progress and discuss efforts underway to reverse this trend. Highlights include presentations about:

- Identifying AD even before clinical symptoms are apparent, when treatments are most likely to be effective.
- New neuroimaging and biomarker technologies and their potential to make clinical trials more informative and successful.
- The latest data from ongoing treatment trials, including new and old drugs, vaccines, vitamins, and nutraceuticals.
- Novel treatment approaches and new conceptual models of dementia.
- Clinical trials for other forms of dementia, particularly Frontotemporal Degeneration (FTD).

Keynote presentations will be delivered by two international leaders in AD therapy research. Paul Aisen, M.D., director of the Alzheimer's Disease Cooperative Study and Professor of Neuroscience at UCSD will deliver the opening keynote address, "The Evolution of AD Trials" on Thursday, November 3<sup>rd</sup> at 8:15 a.m. The closing keynote address, "Pre-Clinical AD: What Do the Data Show" will be delivered by Ronald Petersen, M.D., Ph.D., director of the Mayo Clinic Alzheimer's Disease Research Center and Professor of Neurology on Thursday, November 3<sup>rd</sup> at 5:30 p.m.

The convention program is available on line at <http://www.ctad.fr/>. Media representatives are invited to attend CTAD 2011 with complementary registration. To register, contact [ctad@ant-congres.com](mailto:ctad@ant-congres.com). Pre-registered reporters will receive news releases on selected presentations in advance by e-mail. News releases will also be available on-site in the press room and will be posted on-line at the time of presentation. All sessions are embargoed for the time of presentation unless otherwise noted.

CTAD 2011 is sponsored by the University of California, San Diego School of Medicine, Montpellier and Toulouse European Alzheimer's Disease Consortium (EADC).



Paul S. Aisen, M.D.



Jacques Touchon, MD, PhD



Bruno Vellas, MD, PhD